Navigation Links
Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
Date:3/3/2009

- 31% COMPLETE RESPONSE RATE

- MEDIAN SURVIVAL OF 10.5 MONTHS IN COMPLETE RESPONDERS

- FINAL DATA TARGETED FOR 2009 ASH ANNUAL MEETING

SOUTH SAN FRANCISCO, Calif., March 3 /PRNewswire-FirstCall/ -- Hana Biosciences (Nasdaq: HNAB) today announced new positive preliminary efficacy results from a planned interim analysis of the ongoing pivotal rALLy clinical trial evaluating Marqibo(R) (vincristine sulfate liposomes injection) for the treatment of adult acute lymphoblastic leukemia (ALL) in second relapse. The analysis revealed that nine patients, or 31 percent, of the first 29 evaluable subjects achieved a complete response (CR) or CR without full blood count recovery (CRi). The estimated median overall survival (OS) in responders was 10.5 months compared to 5.1 months in non-responders at the time of the data cutoff. Because six of the nine CRs were still alive at that time, the median OS in this group may prove to be longer.

Since the outset of the rALLy trial, the target response rate for the study has been 16% complete responses (i.e., CR or CRi), which equates to nine or more out of the target evaluable population of 56 subjects. Completion of rALLy will satisfy the Company's need for greater than 100 Marqibo-treated adult ALL patients and catalyze the completion and submission of a New Drug Application for accelerated approval.

"We are strongly encouraged by these excellent preliminary results that show we have already met our overall study goal with regards to the number of complete responses in the first 29 patients, and importantly corroborate previously reported Marqibo activity in past clinical trials," said Steven R. Deitcher, M.D., president and chief executive officer. "These data fully support our plans to submit a New Drug Application for accelerated approval of
'/>"/>

SOURCE Hana Biosciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
2. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
3. YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
4. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
5. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
6. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
7. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
8. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
9. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
10. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
11. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... and SAN DIEGO , Dec. ... PHG ; AEX: PHIA) and Volcano Corporation (NASDAQ: ... measurement solutions for cardiovascular applications, today announced that they have ... Philips will commence a tender offer to acquire all of ... per share, or a total equity purchase price of USD ...
(Date:12/17/2014)... NASHVILLE, Tenn. , Dec. 17, 2014  Strategic ... health management software solutions, today announced a strategic agreement ... the New Jersey regional marketplace.  ... and enhance the health and wellness solutions QualCare brings ... and the surrounding region. QualCare ...
(Date:12/17/2014)... SCOTTSDALE, Ariz. , Dec. 17, 2014 /PRNewswire/ ... of state-of-the-art interactive music products, today announced that ... Ltd, a leading manufacturer and supplier of innovative ... As part of the agreement, RSL ... Facility bundled solution specifically configured for use within ...
Breaking Medicine Technology:Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3
... LITTLE FALLS, N.J., Nov. 5 CANTEL MEDICAL CORP. ... Krakauer, President & CEO, will be presenting at the Sidoti ... formal presentation is scheduled for 9:05 AM ET on Friday, ... a Q & A session immediately following the presentation. In ...
... Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today announced ... voreloxin orphan drug designation for the treatment of acute ... 2 clinical trials of voreloxin in AML: a single-agent ... elderly AML patients unlikely to benefit from standard induction ...
Cached Medicine Technology:Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 2Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 3
(Date:12/20/2014)... MissyDress, a distinguished special dress supplier, has just ... has drastically cut prices to all its prom dresses ... 30, 2015. Many of the hottest styles are sold ... dresses, and more. , A spokesman for MissyDress says, ... A-line princess prom dresses or sweetheart chiffon prom dresses, ...
(Date:12/20/2014)... LunaDress has recently announced its 2015 collection of ... on all of its special occasion dresses & wedding apparel. ... wedding gown. If you have no idea of what to ... different wedding dress styles and our dress experts are here ... current special offer, up to 80% off," the CEO of ...
(Date:12/20/2014)... -- The holidays can be anything but joyous for ... scented candles and other allergy triggers. "The dust ... been packed away in dank basements or dusty attics ... Dr. Rachna Shah, an affiliate faculty member at Loyola ... news release. Shah, who is also an allergist ...
(Date:12/20/2014)... Angeldress.co.uk, the distinguished wedding dress manufacturer and ... fans. The company has recently updated its official blog ... holiday season, Angeldress Blog has recommended some ... Angeldress.co.uk prides itself in offering a huge selection of ... the company’s outfits are very carefully selected based on ...
(Date:12/20/2014)... The aftermath of the November 24th hack on Sony ... Hollywood, but worldwide. As reported in the Los ... attack are starting a finger-pointing game which could put some ... are not the only ones affected, regular employees who had ... times ahead, agents and lawyers could be in for some ...
Breaking Medicine News(10 mins):Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2Health News:Holiday Trimmings Can Trigger Allergies 2Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5
... today said that a district court in the US has ... by Sanofi-Aventis and King Pharmaceuticals. // ,The company ... for the Eastern District of Virginia has issued an opinion ... No - 5061722 relating to Altace (Ramipril) drug and found ...
... Newborns who are breast fed experience less pain during ... by Canadian scientists.// ,Data from 1000 newborns ... effectiveness of breast milk and breast-feeding was compared to ... experienced by infants when blood samples were taken from ...
... According to a study conducted by LaSalle Bank in Chicago it ... and few grocery stores// are at an increased risk of dying ... is found to be a rise in the number of premature ... the residents were found to be obese and also suffer from ...
... Maharashtra are to meet in Bangalore next month to discuss ... has ravaged the four states and has infected lakhs of ... through Kolkata in 1954-55. ,Andhra Pradesh Health Minister ... in a representative at the meeting. Chikungunya was confined to ...
... liver disorders due to their consumption of a herbal remedy ... alert was issued by the Medicines and Healthcare products Regulatory ... soon appear on all products containing the plant extract. Black ... black snakeroot, rattlesnake root and squawroot, and has a market ...
... The Madhya Pradesh government Tuesday ascribed the increase in the ... 1,783 this year - to an increase in the number ... attention motion by Congress legislators Sajjan Singh Verma and Govind ... HIV/AIDS, Health Minister Ajay Vishnoi said: "The number of HIV ...
Cached Medicine News:Health News:Breast-fed Babies Experience Less Pain during Blood Tests 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: